Eribulin Mesylate 0.5 mg
Introduction
Reliable access to quality-assured oncology medicines is an important consideration for hospitals, pharmaceutical importers, healthcare distributors, and institutional procurement organisations. When sourcing injectable cancer medicines internationally, buyers must evaluate product specifications, manufacturer credentials, quality documentation, storage requirements, and destination-market regulations before confirming an order.
India has an established pharmaceutical manufacturing and export industry, including manufacturers of finished injectable medicines. For eligible international buyers, Indian pharmaceutical suppliers may offer sourcing options for oncology products, subject to product availability, manufacturer requirements, and applicable export and import regulations.
Dolphin Pharmaceuticals, based in Surat, Gujarat, India, offers pharmaceutical products across multiple therapeutic categories. International buyers searching for an eribulin mesylate 0.5 mg/mL injection exporter from India can contact the company to enquire about potential sourcing options. The exact product, manufacturer, current availability, documentation, and eligibility for export to the intended destination must be confirmed directly.
This guide explains the key considerations involved in sourcing eribulin mesylate injection, including product identification, quality verification, documentation, storage, transportation, and international procurement planning.
Key Highlights
- Generic name: Eribulin mesylate injection.
- Common concentration: 0.5 mg/mL.
- Common presentation: 1 mg in a 2 mL single-dose vial.
- Dosage form: Sterile solution for intravenous administration.
- Therapeutic category: Antineoplastic medicine; microtubule inhibitor.
- Approved uses: Include certain cases of metastatic breast cancer and unresectable or metastatic liposarcoma, depending on the applicable product approval.
- Potential buyers: Authorised pharmaceutical importers, oncology medicine distributors, hospital procurement teams, and eligible institutional buyers.
- Important procurement checks: Manufacturer verification, batch documentation, product registration, storage conditions, remaining shelf life, and import eligibility.
- Supplier enquiry: Contact Dolphin Pharmaceuticals to confirm whether the specific product can be sourced for the intended market.
These details describe a commonly referenced presentation. Buyers should verify the exact product label, strength, pack configuration, approved indications, and regulatory status before procurement.
Understanding Eribulin Mesylate Injection
Eribulin mesylate is an antineoplastic medicine belonging to the microtubule inhibitor class. It interferes with microtubule dynamics, which play a role in cell division.
Depending on the applicable product approval, eribulin injection is indicated for selected patients with metastatic breast cancer who have previously received specified chemotherapy regimens. Certain product approvals also include unresectable or metastatic liposarcoma following prior treatment.
The exact approved indications may differ between countries. Buyers should consult the applicable product information rather than assuming that every eribulin product has identical authorisations.
Eribulin mesylate injection is administered intravenously by qualified healthcare professionals. It is not intended for self-administration, and its use requires appropriate clinical assessment and monitoring.
For pharmaceutical procurement teams, accurate product identification is essential because the product's concentration, total vial content, formulation, manufacturer, and packaging must match the purchasing specification.
Eribulin Mesylate Injection: Product Details
The following information can help buyers prepare a product-specific procurement enquiry.
- Generic name: Eribulin mesylate.
- Common concentration: 0.5 mg/mL.
- Common total vial content: 1 mg in 2 mL.
- Dosage form: Sterile solution for injection.
- Route of administration: Intravenous.
- Therapeutic category: Antineoplastic medicine; microtubule inhibitor.
- Approved indications: Depend on the product and destination-market authorisation.
- Packaging: Commonly supplied in a single-dose vial; confirm the actual presentation offered.
- Manufacturer: Verify the legal manufacturer and manufacturing site.
- Storage: Follow the approved label for the exact product. Some presentations specify controlled room-temperature storage and prohibit freezing or refrigeration.
- Shelf life: Confirm the expiry date and minimum remaining shelf life required by the importer.
- Quality documentation: Request the applicable product and batch records.
- Availability: Confirm directly with the supplier.
- Export eligibility: Verify the product's regulatory status and import requirements in the destination country.
Important strength clarification: The expression “eribulin mesylate 0.5 mg injection” may be used informally when referring to a 0.5 mg/mL concentration. A commonly referenced presentation contains 0.5 mg per mL and 1 mg in a total volume of 2 mL. Buyers should specify both the concentration and total vial content to avoid ordering errors.
Why Consider an Indian Pharmaceutical Exporter?
International pharmaceutical buyers may evaluate suppliers from India when developing sourcing strategies for finished medicines. However, supplier selection should be based on verifiable product information, manufacturer credentials, quality documentation, and regulatory compliance rather than country of origin alone.
1. Access to Pharmaceutical Sourcing Options
India has pharmaceutical manufacturers and suppliers operating across various therapeutic categories, including selected oncology products.
Depending on their portfolios and supply arrangements, suppliers may be able to review enquiries for specific injectable medicines.
To support an accurate quotation, buyers should provide the generic name, concentration, total vial content, required quantity, preferred manufacturer, packaging requirements, and destination country.
2. Manufacturer Transparency
The exporter and actual medicine manufacturer may be different organisations. A pharmaceutical exporter may source a finished product from a third-party manufacturer.
Buyers should verify the manufacturer's legal name, manufacturing site, product label, and relevant authorisations. The supporting documentation should correspond to the exact medicine being offered.
3. Quality Documentation
Injectable oncology medicines require careful product verification. Buyers should request the documentation applicable to the specific product, manufacturer, batch, and destination market.
Depending on the transaction, this may include product specifications, batch details, a Certificate of Analysis, and relevant manufacturing or quality certificates.
Documentation should be reviewed for consistency before the shipment is approved.
4. International Supply Coordination
International pharmaceutical procurement requires coordination between the exporter, importer, logistics provider, and regulatory authorities.
Buyers should discuss quotation validity, payment terms, order quantities, packaging, lead times, storage requirements, shipping arrangements, and document responsibilities before confirming an order.
Clear written terms can help reduce misunderstandings during procurement and shipment planning.
Dolphin Pharmaceuticals: Oncology Medicine Sourcing Enquiries
Dolphin Pharmaceuticals is based in Surat, Gujarat, India, and offers pharmaceutical products across multiple therapeutic categories.
For buyers searching for an eribulin mesylate injection exporter from India, the company can be contacted to discuss the specific product requirement and potential sourcing arrangements.
Before proceeding, buyers should request confirmation of:
- Whether eribulin mesylate injection can be sourced.
- The exact concentration and total vial content.
- The brand name, where applicable.
- The actual manufacturer and manufacturing site.
- Current availability and quotation.
- Available pack sizes and minimum order requirements, if applicable.
- Relevant product and batch documentation.
- Storage and transportation requirements.
- Registration or approval status in the destination market.
- Estimated dispatch time and shipping arrangements.
A supplier's general pharmaceutical portfolio does not establish that a particular oncology injection is currently in stock or available for export. Product availability and all commercial details should be confirmed directly before placing an order.
How to Choose a Reliable Eribulin Mesylate Injection Supplier
Selecting a supplier requires a structured assessment of the company, product, and proposed transaction.
Verify Supplier Credentials
Review the supplier's legal business details, relevant licences, and role in the pharmaceutical supply chain. Establish whether the company manufactures the product, distributes it, or exports a medicine manufactured by another organisation.
Where required, verify the relevant authorisations for the manufacturer, exporter, and importing organisation.
Confirm Product Specifications
Check the generic name, concentration, total vial content, dosage form, manufacturer, and packaging configuration.
For eribulin mesylate, distinguish between the concentration of 0.5 mg/mL and the total quantity of medicine in the vial. The commonly referenced 1 mg/2 mL presentation should not be confused with a vial containing only 0.5 mg in total.
Review Quality and Batch Documentation
Request the relevant product and batch documents. Verify that the product name, strength, manufacturer, batch number, expiry information, and other applicable details are consistent.
Any discrepancy should be resolved before the order is approved or the shipment is dispatched.
Evaluate Injectable Product Handling
Because eribulin is supplied as a sterile injectable medicine, buyers should review product-specific requirements for packaging integrity, storage, transport, and handling.
The product should be sourced through authorised pharmaceutical channels, with appropriate procedures for receipt, inspection, storage, and traceability.
Compare Complete Quotations
Compare quotations using the same product specifications and commercial terms.
Consider the unit price, quantity, packaging, remaining shelf life, freight, insurance where applicable, documentation, payment conditions, and expected delivery timeline.
A lower price alone does not demonstrate product quality, authenticity, or regulatory eligibility.
Quality Documentation for Eribulin Mesylate Injection
The documents required for an international shipment depend on the product, manufacturer, transaction, and destination-country requirements.
Commercial Documents
Common commercial records may include:
- Proforma invoice.
- Commercial invoice.
- Packing list.
- Purchase order and agreed sales terms.
- Applicable shipping and transport documents.
Product and Quality Documents
Depending on the transaction and applicable regulations, buyers may need:
- Product specifications and approved product information.
- Manufacturer and manufacturing-site details.
- Batch number and expiry information.
- Certificate of Analysis, where applicable.
- Relevant manufacturing or quality certificates.
- Product registration or approval documentation, where required.
Regulatory Documents
Buyers should establish whether product registration, an import permit, importer authorisation, or additional regulatory documentation is required.
For institutional procurement programmes, additional product qualification or quality-assurance requirements may apply.
Not every document applies to every shipment. The importer should confirm the exact checklist with the relevant authorities and supply-chain partners before dispatch.
Storage, Transportation, and Handling Requirements
Appropriate storage and transportation are essential for maintaining the quality of injectable medicines.
Storage Conditions
Storage instructions must follow the approved label for the exact product supplied. Different eribulin presentations may have product-specific labelling, so buyers should not assume that all products have identical storage conditions.
Some commonly referenced presentations specify controlled room-temperature storage and instruct users not to freeze or refrigerate the medicine. The supplied product's label takes precedence.
Packaging Integrity
Check that the packaging configuration is suitable for the intended market and that the product can be inspected upon receipt.
Vial integrity, labelling, batch identification, and expiry information should be verified according to the receiving organisation's procedures.
Shelf-Life Management
Confirm the batch expiry date and any minimum remaining shelf-life requirements before accepting the quotation.
International transit, customs clearance, and local distribution should be considered when planning the shipment.
Cytotoxic Medicine Handling
Eribulin mesylate is a cytotoxic medicine. Its storage, preparation, administration, and disposal require appropriate procedures consistent with the product information and applicable healthcare and workplace-safety requirements.
Pharmaceutical exporters and logistics partners should coordinate the required handling information with authorised importers and healthcare institutions.
Shipping Coordination
Agree on the shipping method, dispatch timeline, packaging arrangements, documentation responsibilities, and any product-specific transport requirements before shipment.
The importer should ensure that the receiving facility can maintain the required conditions throughout storage and distribution.
Regulatory Compliance for International Oncology Medicine Exports
Pharmaceutical exports and imports are governed by the laws and procedures of the countries involved. A medicine being available in India does not automatically mean that it is approved for import or sale in another market.
Before confirming an order, buyers should verify:
- Whether the specific eribulin product is registered or otherwise authorised in the destination country.
- Whether an import permit or additional approval is required.
- Whether the importing organisation is authorised to receive and distribute the medicine.
- Which product, manufacturer, and quality documents must be submitted.
- Whether packaging and labelling meet local requirements.
- Whether additional conditions apply to injectable or cytotoxic medicines.
Where institutional or public-sector procurement requirements apply, buyers should also check any supplier qualification or product quality-assurance criteria.
Regulatory verification should be completed before the shipment is arranged.
How to Request a Quotation from Dolphin Pharmaceuticals
A detailed enquiry helps the supplier assess the product requirement and clarify whether a suitable sourcing option may be available.
International buyers should provide:
- Generic medicine name: eribulin mesylate.
- Required concentration: for example, 0.5 mg/mL.
- Total vial content: for example, 1 mg/2 mL.
- Preferred brand or manufacturer, if applicable.
- Required quantity.
- Destination country.
- Packaging and remaining shelf-life requirements.
- Known registration or import requirements.
- Required quality and regulatory documentation.
- Preferred delivery schedule.
Buyers should request written confirmation of the exact product, actual manufacturer, availability, quotation, supporting documents, and export eligibility.
This information allows the buyer to compare the proposed supply with the original procurement specification before approving an order.
Frequently Asked Questions
1. What is eribulin mesylate injection used for?
Eribulin mesylate is an antineoplastic medicine used for selected patients with certain cancers, including metastatic breast cancer and, under some product approvals, unresectable or metastatic liposarcoma. Approved indications depend on the destination market and product label.
2. What does eribulin mesylate 0.5 mg/mL mean?
It indicates that each millilitre contains 0.5 mg of eribulin mesylate. A commonly referenced presentation contains 1 mg in a total volume of 2 mL.
3. Is eribulin mesylate supplied as an injection?
Yes. The commonly referenced product is a sterile solution administered intravenously by qualified healthcare professionals.
4. Does Dolphin Pharmaceuticals currently stock eribulin mesylate injection?
Current stock and sourcing availability must be confirmed directly with Dolphin Pharmaceuticals. Buyers should specify the required concentration, total vial content, quantity, preferred manufacturer, and destination country.
5. Which documents should buyers request?
Depending on the product and destination, buyers may need product specifications, manufacturer details, batch information, a Certificate of Analysis where applicable, quality certificates, and the required registration or import documents.
6. How should eribulin mesylate injection be stored?
Follow the approved storage instructions for the exact product supplied. Some presentations specify controlled room-temperature storage and prohibit freezing or refrigeration. Buyers should confirm the label requirements before arranging transport.
7. Can eribulin mesylate injection be exported to every country?
No. Product registration, import permits, importer authorisation, and other requirements vary by destination. Buyers should confirm the relevant requirements before placing an order.
Conclusion
Finding a dependable eribulin mesylate 0.5 mg/mL injection exporter from India requires careful verification of product specifications, manufacturer credentials, quality documentation, storage requirements, regulatory compliance, and international shipping arrangements.
Dolphin Pharmaceuticals, based in Surat, Gujarat, India, can be contacted to discuss potential sourcing requirements for eribulin mesylate injection. Buyers should confirm the exact concentration, total vial content, manufacturer, current availability, supporting documents, commercial terms, and destination-market eligibility before finalising an order.
For pharmaceutical importers, oncology distributors, hospital procurement teams, and eligible institutional buyers, a clear product specification and documented supplier review can help support a transparent and well-organised procurement process.
Planning an eribulin mesylate procurement enquiry? Prepare the required concentration, total vial content, quantity, preferred manufacturer, destination country, and documentation requirements so that Dolphin Pharmaceuticals can assess the request and clarify the next steps.
Disclaimer: This article is intended for pharmaceutical procurement and general informational purposes only. Eribulin mesylate is a prescription cytotoxic medicine that must be handled and administered by appropriately qualified healthcare professionals. Product availability, approval, and export eligibility must be independently confirmed.
My Company Name - Dolphin Pharmaceuticals
My Website - https://www.dolphinpharma.in/